* The image above is an example of eyelashes only. Not intended to show effects of LATISSE®
Most women turn to cosmetics when they want to enhance the length and fullness of their eyelashes, but for some women, these products can’t help. For those who suffer from a condition called hypotrichosis, lash growth is inadequate, which can be addressed with Latisse. Latisse is an FDA-approved prescription that when applied to the eyelid nightly, can produce longer, fuller, darker eyelashes. Typically, patients can achieve dramatic results in around 4 months.
How It works
LATISSE® solution works gradually, with full results at week 16. Once you begin applying, you must continue the topical solution each night and follow the directions for best results. If you stop using LATISSE® at any time, your eyelashes will return to their previous appearance over several weeks to months.
As the treatment progresses, you'll first begin to see changes in length. Then, gradually, you'll notice more thickness and darkness in your lashes. After week 16, you'll see the full effect of LATISSE® solution. After that, you can talk to Dr. Talbot about ongoing use.
What to expect
Though Latisse is easy to apply, a patient must follow all instructions carefully. A patient must wash hands and face prior to application. The face should be makeup-free and contacts should be removed. Contacts can be put back in 15 minutes after application. Latisse should be applied evenly across the upper eyelid. Provided applicators should be thrown away after each use to keep the medication sterile. Patients should note that Latisse is not recommended to be used on bottom lashes. Full results should be achieved in about 4 months but most patients see an improvement in 3-4 weeks. It is possible that a patient may not obtain the same results on both sets of lashes.
The most common side effects are itchy or red eyes. Less common side effects can include a darkening or redness of the eyelid, eye dryness or eye irritation. If a patient discontinues the use of Latisse, eyelid darkening should be reversed in a few weeks up to a few months. In very rare cases, eye trauma could occur and a patient should seek medical attention immediately.
Warnings and Precautions: In patients using LUMIGAN® (bimatoprost ophthalmic solution) or other prostaglandin analogs for the treatment of elevated intraocular pressure (IOP), the concomitant use of LATISSE® may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including LUMIGAN® for IOP reduction should only use LATISSE® after consulting with their physician and should be monitored for changes to their intraocular pressure. Increased iris pigmentation has occurred when bimatoprost solution was administered. Patients should be advised about the potential for increased brown iris pigmentation, which is likely to be permanent. Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes. The pigmentation is expected to increase as long as bimatoprost is administered, but has been reported to be reversible upon discontinuation of bimatoprost in most patients. There is the potential for hair growth to occur in areas where LATISSE® solution comes in repeated contact with skin surfaces. Apply LATISSE® only to the skin of the upper eyelid margin at the base of the eyelashes. LATISSE® solution should be used with caution in patients with active intraocular inflammation (eg, uveitis) because the inflammation may be exacerbated. LATISSE® contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to application of solution and may be reinserted 15 minutes following its administration. Adverse Reactions: The most frequently reported adverse events were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and erythema of the eyelid. These events occurred in less than 4% of patients. Postmarketing Experience: The following reactions have been identified during postmarketing use of LATISSE® in clinical practice: eye swelling, eyelid edema, hypersensitivity (local allergic reactions), lacrimation increased, madarosis and trichorrhexis (temporary loss of a few eyelashes to loss of sections of eyelashes, and temporary eyelash breakage, respectively), periorbital and lid changes associated with a deepening of the eyelid sulcus, rash (including macular and erythematous), skin discoloration (periorbital), and vision blurred. Please see LATISSE® full Prescribing Information.